Results 101 to 110 of about 13,346 (214)

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

Nature Communications
Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment ...
Guillem Pascual-Pasto, Brendan McIntyre, Margaret G. Hines, Anna M. Giudice, Laura Garcia-Gerique, Jennifer Hoffmann, Pamela Mishra, Stephanie Matlaga, Simona Lombardi, Rawan Shraim, Patrick M. Schürch, Mark Yarmarkovich, Ted J. Hofmann, Fatemeh Alikarami, Daniel Martinez, Matthew Tsang, Luis Gil-de-Gómez, Timothy T. Spear, Kathrin M. Bernt, Adam J. Wolpaw, Dimiter S. Dimitrov, Wei Li, Kristopher R. Bosse   +22 more
doaj   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Beauty in the Eye of AI: Aligning LLMs and Vision Models with Human Aesthetics in Network Visualization

Computer Graphics Forum, EarlyView.
Abstract Network visualization has traditionally relied on heuristic metrics, such as stress, under the assumption that optimizing them leads to aesthetic and informative layouts. However, no single metric consistently produces the most effective results.
X. Li, P. Zhang, X. Wang, H. Shen, Y. Hu
wiley   +1 more source

Epitaxial growth of Gd2-xCexCuO4 thin films

, 2008
We have grown (001)-oriented thin films of Gd2-xCexCuO4with cerium composition 0 < x < 0.2 by state-of-the-art reactive molecular beam epitaxy and characterized them by x-ray diffraction and transport measurements.
Kurian, J., Naitoh, M., Naito, M., Alff, L., Krockenberger, Y.   +4 more
core   +1 more source

CD24 Positive Nucleus Pulposus Cells in Adult Human Intervertebral Discs Maintain a More Notochordal Phenotype Than GD2 Positive Cells

JOR Spine
Background Notochordal cells (NCs) present in the nucleus pulposus (NP) of the developing human intervertebral disc (IVD) disappear during the first decade of life.
Andra‐Maria Ionescu, Pauline Baird, Sonal Patel, Gareth Howell, Judith A. Hoyland, Stephen M. Richardson   +5 more
doaj   +1 more source

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Journal of Hematology & Oncology, 2020
Background The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was ...
Jeong A. Park, Nai-Kong V. Cheung
doaj   +1 more source

Peptide mimicry of GD2 binding to ME36.1.

, 2012
A. Hydrogen bonding site map describing peptide (LDVVLAWRDGLSGAS) recognition by ME36.1. B. van der Waals interaction site map describing peptide recognition by ME36.1. C. Comparison of hydrogen bonding site maps describing GD2 and peptide recognition. D.
Elizabeth Yuriev (169377), Paul A. Ramsland (169383), Mark Agostino (169368)   +2 more
core   +1 more source